In low-income and middle-income countries, dolutegravir is replacing older antiretroviral therapies (ART) with less efficacy and greater toxicity. WHO indicates first-line and second-line regimens containing dolutegravir as preferred regimens. In March 2018, the Ugandan Government recommended initiating dolutegravir-based regimens among treatment-naive patients and transitioning eligible treatment-experienced patients from various first-line regimens, focusing initially on specialised centres, including the Infectious Diseases Institute at Makerere University (Kampala, Uganda). By March 2019, 3417 of 6648 patients on first-line regimens in the Infectious Diseases Institute were initiated on dolutegravir.

中文翻译：

---

HIV患者中与Dolutegravir相关的高血糖症。

在低收入和中等收入国家，dolutegravir正在以疗效更差，毒性更大的方式代替较旧的抗逆转录病毒疗法（ART）。WHO指出一线和二线方案均以dolutegravir为首选方案。2018年3月，乌干达政府建议在未接受过治疗的患者中开始使用基于dolutegravir的治疗方案，并从各种一线治疗方案中转移合格的有治疗经验的患者，最初将重点放在专门的中心上，包括马克雷雷大学传染病研究所（乌干达坎帕拉） ）。到2019年3月，在dolutegravir上启动了传染病研究所一线治疗方案中6648例患者中的3417例。